Established esophageal adenocarcinoma cell lines Eso26, OACM 5.1C and Flo1 were used as a model to demonstrate the relevance of TROP2 expression levels to the effectiveness of treatments with sacituzumab govitecan (SG). Here, TACSTD2 is linked to esophageal adenocarcinoma.